X0306 4 2014-12-08 0 0001372299 HISTOGENICS CORP HSGX 0001626777 Wilmslow Estates Ltd C/O HISTOGENICS CORPORATION 830 WINTER STREET, 3RD FLOOR WALTHAM MA 02451 0 0 1 0 Common Stock 2014-12-08 4 C 0 747000 A 1036244 D Common Stock 2014-12-08 4 C 0 492618 A 1528862 D Common Stock 2014-12-08 4 X 0 11502 0.76 A 1540364 D Common Stock 2014-12-08 4 S 0 792 11.00 D 1539572 D Common Stock 2014-12-08 4 P 0 394918 11.00 A 1934490 D Common Stock 2014-12-08 4 J 0 17383 D 1917107 D Series A Preferred Stock 2014-12-08 4 C 0 747000 0.00 D Common Stock 747000 0 D Series A-1 Preferred Stock 2014-12-08 4 C 0 492618 0.00 D Common Stock 492618 0 D Common Stock Warrant (Right to Buy) 0.76 2014-12-08 4 X 0 11502 0.00 D Common Stock 11502 0 D Reflects a 10.804-to-1 reverse stock split effected on November 14, 2014. Each outstanding share of Series A Preferred Stock and Series A-1 Preferred Stock automatically converted on a 1:1 basis into the Issuer's common stock, immediately prior to the closing of the Issuer's initial public offering, for no additional consideration and including accrued dividends. These shares have no expiration date. The Common Stock Warrant was automatically net exercised, immediately prior to the closing of the Issuer's initial public offering. The Reporting Person paid the exercise price on a cashless basis, resulting in the Issuer's withholding of 792 of the warrant shares to pay the exercise price and issuing the Reporting Person the remaining 10,710 shares. The expiration date of the warrant is upon the consummation of the Issuer's initial public offering or a liquidity event (as described in such warrant). These shares of Common Stock were transferred to a strategic partner of the Issuer to satisfy the Reporting Person's contractual obligations under certain agreements between the Issuer, the Reporting Person, certain of the Issuer's other stockholders, and such strategic partner. /s/ Cora Binchy /s/ Ian Ferguson, For: Chaumont (Directors) Limited, The corporate director of the Reporting Person 2014-12-08